Your browser doesn't support javascript.
loading
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail, D J; Pilié, P G; Rashid, N U; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, A B; Lim, B; Ueno, N T; Litton, J K; Ferrarotto, R; Chang, J T; Moulder, S L; Lin, S-Y.
Afiliación
  • McGrail DJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
  • Pilié PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rashid NU; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
  • Voorwerk L; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Slagter M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.
  • Kok M; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Jonasch E; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Khasraw M; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
  • Heimberger AB; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Chang JT; Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Moulder SL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Lin SY; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.
Ann Oncol ; 32(5): 661-672, 2021 05.
Article en En | MEDLINE | ID: mdl-33736924
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido